Considerations for Rescinding Breakthrough Therapy Designation
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
June 24, 2022
June 24, 2022
adc0ae37-722c-4b21-90ea-5a2087f771f0
Related Documents
Drug Master Files Guidance for Industry
Guidance DocumentNovember 15, 2019Center for Drug Evaluation and Research
Accelerated Approval – Expedited Program for Serious Conditions
Guidance DocumentDecember 5, 2024Center for Drug Evaluation and Research
Nonproprietary Naming of Biological Products: Update Guidance for Industry
Guidance DocumentMarch 8, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.